Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 294

1.

Activated Eosinophils Exert Antitumorigenic Activities in Colorectal Cancer.

Reichman H, Itan M, Rozenberg P, Yarmolovski T, Brazowski E, Varol C, Gluck N, Shapira S, Arber N, Qimron U, Karo-Atar D, Lee JJ, Munitz A.

Cancer Immunol Res. 2019 Mar;7(3):388-400. doi: 10.1158/2326-6066.CIR-18-0494. Epub 2019 Jan 21.

PMID:
30665890
2.

Deferasirox selectively induces cell death in the clinically relevant population of leukemic CD34+CD38- cells through iron chelation, induction of ROS, and inhibition of HIF1α expression.

Shapira S, Raanani P, Samara A, Nagler A, Lubin I, Arber N, Granot G.

Exp Hematol. 2019 Feb;70:55-69.e4. doi: 10.1016/j.exphem.2018.10.010. Epub 2018 Nov 8.

PMID:
30414989
3.

Novel prep-less X-ray imaging capsule for colon cancer screening: a feasibility study.

Gluck N, Half EE, Bieber V, Schwartz D, Ron Y, Gralnek I, Klein A, Lachter J, Levy MS, Moshkowitz M, Arber N.

Gut. 2018 May 21. pii: gutjnl-2018-316127. doi: 10.1136/gutjnl-2018-316127. [Epub ahead of print] No abstract available.

PMID:
29785966
4.

Impaired bone healing at tooth extraction sites in CD24-deficient mice: A pilot study.

Avivi-Arber L, Avivi D, Perez M, Arber N, Shapira S.

PLoS One. 2018 Feb 1;13(2):e0191665. doi: 10.1371/journal.pone.0191665. eCollection 2018.

5.

Of mice and men: a novel dietary supplement for the treatment of ulcerative colitis.

Shapira S, Leshno A, Katz D, Maharshak N, Hevroni G, Jean-David M, Kraus S, Galazan L, Aroch I, Kazanov D, Hallack A, Becker S, Umanski M, Moshkowitz M, Dotan I, Arber N.

Therap Adv Gastroenterol. 2017 Nov 28;11:1756283X17741864. doi: 10.1177/1756283X17741864. eCollection 2018.

6.

Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort.

Church RJ, Kullak-Ublick GA, Aubrecht J, Bonkovsky HL, Chalasani N, Fontana RJ, Goepfert JC, Hackman F, King NMP, Kirby S, Kirby P, Marcinak J, Ormarsdottir S, Schomaker SJ, Schuppe-Koistinen I, Wolenski F, Arber N, Merz M, Sauer JM, Andrade RJ, van Bömmel F, Poynard T, Watkins PB.

Hepatology. 2019 Feb;69(2):760-773. doi: 10.1002/hep.29802. Epub 2018 Jun 27.

PMID:
29357190
7.

Selective eradication of cancer cells by delivery of adenovirus-based toxins.

Shapira S, Shapira A, Kazanov D, Hevroni G, Kraus S, Arber N.

Oncotarget. 2017 Jun 13;8(24):38581-38591. doi: 10.18632/oncotarget.16934.

8.

Radiographic capsule-based system for non-cathartic colorectal cancer screening.

Kimchy Y, Lifshitz R, Lewkowitz S, Bertuccio G, Arber N, Gluck N, Pickhardt PJ.

Abdom Radiol (NY). 2017 May;42(5):1291-1297. doi: 10.1007/s00261-016-1026-y.

PMID:
28054186
9.

Prevalence of colorectal neoplasms in young, average risk individuals: A turning tide between East and West.

Leshno A, Moshkowitz M, David M, Galazan L, Neugut AI, Arber N, Santo E.

World J Gastroenterol. 2016 Aug 28;22(32):7365-72. doi: 10.3748/wjg.v22.i32.7365.

10.

Terpinen-4-ol: A Novel and Promising Therapeutic Agent for Human Gastrointestinal Cancers.

Shapira S, Pleban S, Kazanov D, Tirosh P, Arber N.

PLoS One. 2016 Jun 8;11(6):e0156540. doi: 10.1371/journal.pone.0156540. eCollection 2016.

11.

Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury.

Mikus M, Drobin K, Gry M, Bachmann J, Lindberg J, Yimer G, Aklillu E, Makonnen E, Aderaye G, Roach J, Fier I, Kampf C, Göpfert J, Perazzo H, Poynard T, Stephens C, Andrade RJ, Lucena MI, Arber N, Uhlén M, Watkins PB, Schwenk JM, Nilsson P, Schuppe-Koistinen I.

Liver Int. 2017 Jan;37(1):132-140. doi: 10.1111/liv.13174. Epub 2016 Jun 22.

12.

Feasibility study of minimal prepared hydroflush screening colonoscopy.

Moshkowitz M, Fokra A, Itzhak Y, Arber N, Santo E.

United European Gastroenterol J. 2016 Feb;4(1):105-9. doi: 10.1177/2050640615583409. Epub 2015 Apr 28.

13.

A novel prepless X-ray imaging capsule for colon cancer screening.

Gluck N, Shpak B, Brun R, Rösch T, Arber N, Moshkowitz M.

Gut. 2016 Mar;65(3):371-3. doi: 10.1136/gutjnl-2015-310893. Epub 2015 Dec 1. No abstract available.

14.

Delayed Wound Healing in Heat Stable Antigen (HSA/CD24)-Deficient Mice.

Shapira S, Ben-Amotz O, Sher O, Kazanov D, Mashiah J, Kraus S, Gur E, Arber N.

PLoS One. 2015 Oct 6;10(10):e0139787. doi: 10.1371/journal.pone.0139787. eCollection 2015.

15.

Actionable clinical decisions based on comprehensive genomic evaluation in asymptomatic adults.

Pillar N, Isakov O, Weissglas-Volkov D, Botchan S, Friedman E, Arber N, Shomron N.

Mol Genet Genomic Med. 2015 Sep;3(5):433-9. doi: 10.1002/mgg3.154. Epub 2015 May 6.

16.

The APC I1307K allele conveys a significant increased risk for cancer.

Leshno A, Shapira S, Liberman E, Kraus S, Sror M, Harlap-Gat A, Avivi D, Galazan L, David M, Maharshak N, Moanis S, Arber N, Moshkowitz M.

Int J Cancer. 2016 Mar 15;138(6):1361-7. doi: 10.1002/ijc.29876. Epub 2015 Oct 13.

17.

CD24 and APC Genetic Polymorphisms in Pancreatic Cancers as Potential Biomarkers for Clinical Outcome.

Shamai S, Nabiochtchikov I, Kraus S, Zigdon S, Kazanov D, Itzhak-Klutch M, Eizner C, Arber N, Geva R.

PLoS One. 2015 Sep 22;10(9):e0134469. doi: 10.1371/journal.pone.0134469. eCollection 2015.

18.

Can We Select Patients for Colorectal Cancer Prevention with Aspirin?

Kraus S, Sion D, Arber N.

Curr Pharm Des. 2015;21(35):5127-34. Review.

PMID:
26369678
19.

Association of CD24 and the adenomatous polyposis coli gene polymorphisms with oral lichen planus.

Kaplan I, Nabiochtchikov I, Leshno A, Moshkowitz M, Shlomi B, Kleinman S, Dagan Y, Meshiach Y, Galazan L, Arber N, Avivi-Arber L, Kraus S.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 Sep;120(3):378-85. doi: 10.1016/j.oooo.2015.05.015. Epub 2015 May 28.

PMID:
26187149
20.

Predictive Levels of CD24 in Peripheral Blood Leukocytes for the Early Detection of Colorectal Adenomas and Adenocarcinomas.

Kraus S, Shapira S, Kazanov D, Naumov I, Moshkowitz M, Santo E, Galazan L, Geva R, Shmueli E, Hallack A, Arber N.

Dis Markers. 2015;2015:916098. doi: 10.1155/2015/916098. Epub 2015 May 11.

21.

Corrigendum: methotrexate in chronic active Crohn's disease: a double-blind, randomized, israeli multicenter trial.

Oren R, Moshkowitz M, Odes S, Becker S, Keter D, Pomeranz I, Shirin C, Reisfeld I, Broide E, Lavy A, Fich A, Eliakim R, Patz J, Villa Y, Arber N, Gilat T.

Am J Gastroenterol. 2015 Apr;110(4):608. doi: 10.1038/ajg.2015.61. No abstract available.

PMID:
25853210
22.

Incidence of colorectal neoplasms among male pilots.

Moshkowitz M, Toledano O, Galazan L, Hallak A, Arber N, Santo E.

World J Gastroenterol. 2014 Jul 21;20(27):9116-20. doi: 10.3748/wjg.v20.i27.9116.

23.

Lack of CD24 expression in mice reduces the number of leukocytes in the colon.

Bretz NP, Salnikov AV, Doberstein K, Garbi N, Kloess V, Joumaa S, Naumov I, Boon L, Moldenhauer G, Arber N, Altevogt P.

Immunol Lett. 2014 Sep;161(1):140-8. doi: 10.1016/j.imlet.2014.06.004. Epub 2014 Jun 20.

PMID:
24956310
24.

Aspirin but not meloxicam attenuates early atherosclerosis in apolipoprotein E knockout mice.

Kraus S, Naumov I, Shapira S, Kazanov D, Aroch I, Afek A, Eisenberg O, George J, Arber N, Finkelstein A.

Isr Med Assoc J. 2014 Apr;16(4):233-8.

25.

Translation strategy for the qualification of drug-induced vascular injury biomarkers.

Bendjama K, Guionaud S, Aras G, Arber N, Badimon L, Bamberger U, Bratfalean D, Brott D, David M, Doessegger L, Firat H, Gallas JF, Gautier JC, Hoffmann P, Kraus S, Padro T, Saadoun D, Szczesny P, Thomann P, Vilahur G, Lawton M, Cacoub P.

Toxicol Pathol. 2014 Jun;42(4):658-71. doi: 10.1177/0192623314527644. Epub 2014 Apr 24.

PMID:
24771082
26.

Role of CD24 polymorphisms in the susceptibility to inflammatory bowel disease.

Lisiansky V, Kraus S, Naumov I, Kazanov D, Nabiochtchikov I, Toledano O, Leshno M, Avivi D, Dotan I, Arber N, Moshkowitz M.

Int J Biol Markers. 2014 Mar 24;29(1):e62-8. doi: 10.5301/jbm.5000072.

PMID:
24557789
27.

Peptides for diagnosis and treatment of colorectal cancer.

Shapira S, Fokra A, Arber N, Kraus S.

Curr Med Chem. 2014;21(21):2410-6. Review.

PMID:
24524764
28.

CD24 knockout prevents colorectal cancer in chemically induced colon carcinogenesis and in APC(Min)/CD24 double knockout transgenic mice.

Naumov I, Zilberberg A, Shapira S, Avivi D, Kazanov D, Rosin-Arbesfeld R, Arber N, Kraus S.

Int J Cancer. 2014 Sep 1;135(5):1048-59. doi: 10.1002/ijc.28762. Epub 2014 Mar 21.

29.

Recent advances in personalized colorectal cancer research.

Kraus S, Nabiochtchikov I, Shapira S, Arber N.

Cancer Lett. 2014 May 28;347(1):15-21. doi: 10.1016/j.canlet.2014.01.025. Epub 2014 Jan 31. Review.

PMID:
24491406
30.

CD24 gene polymorphism--a novel prognostic factor in esophageal cancer.

Sadot E, Kraus S, Stein M, Naboishchikov I, Toledano O, Kazanov D, Arber N, Kashtan H.

Int J Biol Markers. 2014 Mar 24;29(1):e49-54. doi: 10.5301/jbm.5000071.

PMID:
24474454
31.

The APC p.I1307K polymorphism is a significant risk factor for CRC in average risk Ashkenazi Jews.

Boursi B, Sella T, Liberman E, Shapira S, David M, Kazanov D, Arber N, Kraus S.

Eur J Cancer. 2013 Nov;49(17):3680-5. doi: 10.1016/j.ejca.2013.06.040. Epub 2013 Jul 26.

PMID:
23896379
32.

Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study.

Kraus S, Hummler S, Toriola AT, Poole EM, Scherer D, Kotzmann J, Makar KW, Kazanov D, Galazan L, Naumov I, Coghill AE, Duggan D, Gigic B, Arber N, Ulrich CM.

Pharmacogenet Genomics. 2013 Aug;23(8):428-437. doi: 10.1097/FPC.0b013e3283631784.

33.

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.

Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C.

Lancet. 2013 Aug 31;382(9894):769-79. doi: 10.1016/S0140-6736(13)60900-9. Epub 2013 May 30.

34.

Chemoprevention of gastrointestinal neoplasia.

Half E, Arber N.

Curr Gastroenterol Rep. 2013 May;15(5):320. doi: 10.1007/s11894-013-0320-x. Review.

PMID:
23605648
35.

One stop screening for multiple cancers: the experience of an integrated cancer prevention center.

Sella T, Boursi B, Gat-Charlap A, Aroch I, Liberman E, Moshkowitz M, Miller E, Gur E, Inbar R, Blachar A, Mabjeesh NJ, Rosenfeld O, Sperber F, Reiser V, Kleinman S, Jaffa AJ, Bloch M, Ormianer M, Naumov I, Kazanov D, Kraus S, Galazan L, Arber N.

Eur J Intern Med. 2013 Apr;24(3):245-9. doi: 10.1016/j.ejim.2012.12.012. Epub 2013 Jan 9.

PMID:
23312963
36.

Increased expression of CD24 in nonmelanoma skin cancer.

Miller E, Shapira S, Gur E, Naumov I, Kazanov D, Leshem D, Barnea Y, Meshiach Y, Gat A, Sion D, Arber N, Kraus S.

Int J Biol Markers. 2012 Dec 27;27(4):e331-6. doi: 10.5301/JBM.2012.9935.

PMID:
23250778
37.

Gene therapy of pancreatic cancer targeting the K-Ras oncogene.

Lisiansky V, Naumov I, Shapira S, Kazanov D, Starr A, Arber N, Kraus S.

Cancer Gene Ther. 2012 Dec;19(12):862-9. doi: 10.1038/cgt.2012.73. Epub 2012 Oct 26.

PMID:
23099885
38.

COX-2 active agents in the chemoprevention of colorectal cancer.

Kraus S, Naumov I, Arber N.

Recent Results Cancer Res. 2013;191:95-103. doi: 10.1007/978-3-642-30331-9_5. Review.

PMID:
22893201
39.

Involvement of CD24 in angiogenesis in a mouse model of oxygen-induced retinopathy.

Newman H, Shapira S, Spierer O, Kraus S, Rosner M, Pri-Chen S, Loewenstein A, Arber N, Barak A.

Curr Eye Res. 2012 Jun;37(6):532-9. doi: 10.3109/02713683.2011.647226.

PMID:
22577772
40.

The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo.

Arber N, Lieberman D, Wang TC, Zhang R, Sands GH, Bertagnolli MM, Hawk ET, Eagle C, Coindreau J, Zauber A, Lanas A, Levin B.

Clin Ther. 2012 Mar;34(3):569-79. doi: 10.1016/j.clinthera.2012.02.001. Epub 2012 Mar 2.

PMID:
22386831
41.

The role of low-dose aspirin in the prevention of colorectal cancer.

Avivi D, Moshkowitz M, Detering E, Arber N.

Expert Opin Ther Targets. 2012 Mar;16 Suppl 1:S51-62. doi: 10.1517/14728222.2011.647810. Epub 2012 Feb 8. Review.

PMID:
22313430
42.

Chemoprevention for advanced CR neoplasia.

Moshkowitz M, Shapira S, Arber N.

Best Pract Res Clin Gastroenterol. 2011 Aug;25(4-5):623-30. doi: 10.1016/j.bpg.2011.10.011. Review.

PMID:
22122776
43.

Aspirin in the chemoprevention of colorectal neoplasia: an overview.

Chan AT, Arber N, Burn J, Chia WK, Elwood P, Hull MA, Logan RF, Rothwell PM, Schrör K, Baron JA.

Cancer Prev Res (Phila). 2012 Feb;5(2):164-78. doi: 10.1158/1940-6207.CAPR-11-0391. Epub 2011 Nov 14. Review.

44.

Novel approach to abuse the hyperactive K-Ras pathway for adenoviral gene therapy of colorectal cancer.

Naumov I, Kazanov D, Lisiansky V, Starr A, Aroch I, Shapira S, Kraus S, Arber N.

Exp Cell Res. 2012 Jan 15;318(2):160-8. doi: 10.1016/j.yexcr.2011.09.015. Epub 2011 Oct 12.

PMID:
22020090
45.

The CD24 protein inducible expression system is an ideal tool to explore the potential of CD24 as an oncogene and a target for immunotherapy in vitro and in vivo.

Shapira S, Kazanov D, Weisblatt S, Starr A, Arber N, Kraus S.

J Biol Chem. 2011 Nov 25;286(47):40548-55. doi: 10.1074/jbc.M111.286534. Epub 2011 Oct 5.

46.

Small bowel polyposis syndromes.

Arber N, Moshkowitz M.

Curr Gastroenterol Rep. 2011 Oct;13(5):435-41. doi: 10.1007/s11894-011-0218-4. Review.

PMID:
21800071
47.

The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010.

Van Cutsem E, Dicato M, Geva R, Arber N, Bang Y, Benson A, Cervantes A, Diaz-Rubio E, Ducreux M, Glynne-Jones R, Grothey A, Haller D, Haustermans K, Kerr D, Nordlinger B, Marshall J, Minsky BD, Kang YK, Labianca R, Lordick F, Ohtsu A, Pavlidis N, Roth A, Rougier P, Schmoll HJ, Sobrero A, Tabernero J, Van de Velde C, Zalcberg J.

Ann Oncol. 2011 Jun;22 Suppl 5:v1-9. doi: 10.1093/annonc/mdr284.

PMID:
21633049
48.

A generic operational strategy to qualify translational safety biomarkers.

Matheis K, Laurie D, Andriamandroso C, Arber N, Badimon L, Benain X, Bendjama K, Clavier I, Colman P, Firat H, Goepfert J, Hall S, Joos T, Kraus S, Kretschmer A, Merz M, Padro T, Planatscher H, Rossi A, Schneiderhan-Marra N, Schuppe-Koistinen I, Thomann P, Vidal JM, Molac B.

Drug Discov Today. 2011 Jul;16(13-14):600-8. doi: 10.1016/j.drudis.2011.04.011. Epub 2011 May 6. Review.

PMID:
21570476
49.

Gene expression following exposure to celecoxib in humans: pathways of inflammation and carcinogenesis are activated in tumors but not normal tissues.

Sagiv E, Sheffer M, Kazanov D, Shapira S, Naumov I, Kraus S, Domany E, Arber N.

Digestion. 2011;84(3):169-84. doi: 10.1159/000322688. Epub 2011 May 5.

PMID:
21546775
50.

Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial.

Arber N, Spicak J, Rácz I, Zavoral M, Breazna A, Gerletti P, Lechuga MJ, Collins N, Rosenstein RB, Eagle CJ, Levin B.

Am J Gastroenterol. 2011 Jun;106(6):1135-46. doi: 10.1038/ajg.2011.116. Epub 2011 Apr 19.

PMID:
21503000

Supplemental Content

Support Center